PinealaminvsSermorelin

Pinealamin is a low-molecular-weight peptide extract derived from the pineal glands of young cattle, processed to isolate short peptides (typically under 10 kDa) with proposed bioregulatory activity on pineal gland function. Unlike defined Khavinson tripeptides such as pinealon (Glu-Asp-Arg), pinealamin is a complex mixture of multiple peptide species, and its biological activity is attributed to the combined effect of these peptides rather than a single active component.

The proposed mechanism follows the Khavinson bioregulator framework: tissue-derived short peptides preferentially target the same tissue type from which they were extracted, binding to gene promoter regions and modulating expression of genes involved in pineal-specific functions. For pinealamin, this is hypothesised to include regulation of melatonin biosynthesis enzymes (notably AANAT and HIOMT), serotonin-to-melatonin conversion pathways, and the broader hypothalamic-pituitary-pineal axis that governs circadian rhythm.

Clinical positioning is primarily for age-related decline in melatonin secretion and associated sleep disorders in older adults — Russian observational studies have reported improvements in subjective sleep quality and measured melatonin output following pinealamin courses in middle-aged and elderly subjects. As with all Khavinson cytamins, the efficacy and mechanism evidence base sits almost entirely within Russian research traditions and has not been replicated in Western randomised controlled trials. The animal-derived sourcing also raises quality and safety considerations that vary significantly between suppliers, and pharmacopoeial standards for pinealamin do not exist outside Russian regulatory frameworks.

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-44). These 29 residues contain the full biological activity domain required for GHRH receptor activation — the remaining 15 amino acids of native GHRH are not necessary for receptor binding or signal transduction.

Sermorelin binds to the GHRH receptor on anterior pituitary somatotrophs, activating the Gs/adenylyl cyclase pathway to increase intracellular cAMP. This triggers PKA-mediated phosphorylation of CREB and stimulates both GH gene transcription and the release of pre-formed GH vesicles. Because sermorelin works through the body's own regulatory system, GH release occurs in a physiological pulsatile pattern governed by the interplay between GHRH stimulation and somatostatin inhibition — the hypothalamic-pituitary feedback loop remains intact.

This preservation of feedback regulation is sermorelin's primary safety advantage over exogenous GH administration. The pituitary gland can only release as much GH as it has synthesized, providing a natural ceiling effect that prevents supraphysiological GH levels. Somatostatin feedback still functions normally, ensuring appropriate pulse spacing. Additionally, because the pituitary itself is being stimulated rather than bypassed, sermorelin may help maintain or even restore pituitary somatotroph function over time. It was the first GHRH analogue to receive FDA approval (as Geref), specifically for evaluating pituitary GH reserve and treating pediatric GH deficiency, giving it one of the longest clinical track records among GH-stimulating peptides.